Skip to main content
. Author manuscript; available in PMC: 2023 Mar 17.
Published in final edited form as: Am J Ophthalmol. 2018 Feb 28;189:86–95. doi: 10.1016/j.ajo.2018.02.015

FIGURE 4.

FIGURE 4.

Anatomic outcomes in patients with subfoveal hemorrhage owing to neovascular age-related macular degeneration treated with intravitreous injections of a vascular endothelial growth factor neutralizing protein. Points show the mean (±95% confidence interval) central subfield thickness (CST) at baseline and 6, 12, 24, 36, 48, and 60 months after baseline. *P < .001 for difference from baseline by unadjusted mixedeffect regression model.